Total trials
130
Active
36
Phase 3
3
Total enrollment
70,199
Pipeline matrix
Showing 9 of 9 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexmedetomidine prolonged sedation | — | — | — | — | — | 1 | |
| 0.9% saline | — | — | — | — | — | 1 | |
| Aspirin | — | — | — | — | — | 1 | |
| Immunotherapy | — | — | — | — | — | 1 | |
| Semaglutide Subcutaneous | — | — | — | — | — | 1 | |
| Nafamostat | — | — | — | — | — | 1 | |
| Heparin | — | — | — | — | — | 1 | |
| Multicomponent frailty intervention | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | — | 1 |
Next readouts
- 2023-12-30
- 2026-08-01
- 2026-12
- 2026-12-31
- 2027-01-01
- 2027-09-30
- 2027-12-31
Top conditions
- Type 2 Diabetes6
- Pulmonary Embolism6
- Acute Respiratory Distress Syndrome5
- Rectal Cancer4
- Acute Exacerbation of Chronic Obstructive Pulmonary Disease3
- Postoperative Delirium3
- Thromboembolism3
- Obesity3
Frequently asked questions about Beijing Chao Yang Hospital
- How many clinical trials does Beijing Chao Yang Hospital have on ClinicalTrials.gov?
- Beijing Chao Yang Hospital is listed as the lead sponsor on 130 clinical trials in ClinicalTrials.gov, 36 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Beijing Chao Yang Hospital's trials are in Phase 3?
- 3 of Beijing Chao Yang Hospital's trials are in Phase 3, spread across 9 active drug programs.
- What therapeutic areas does Beijing Chao Yang Hospital focus on?
- Beijing Chao Yang Hospital's most-studied conditions on ClinicalTrials.gov are Type 2 Diabetes, Pulmonary Embolism, Acute Respiratory Distress Syndrome, Rectal Cancer, Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
- When are Beijing Chao Yang Hospital's next clinical trial readouts?
- Beijing Chao Yang Hospital has 7 upcoming primary-completion readouts tracked here; the soonest is “Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer”, expected around 2023-12-30.